文献速递肥胖与代谢综合征糖尿病

代谢表型转变与亚临床动脉粥样硬化风险:基于BMI的前瞻性研究

Transition of metabolic phenotypes and risk of subclinical atherosclerosis according to BMI: a prospective study.
PubMed 文献 · Diabetologia · 2020-03-04

在中国6220名基线无心血管疾病的成年人中开展前瞻性研究,肥胖定义为BMI≥25.0 kg/m2,代谢健康定义为NCEP ATP III代谢综合征组分(除腰围外)少于两项。基线代谢健康肥胖(MHO)占16.3%,与亚临床动脉粥样硬化无显著关联;随访4.4年间46.8%的MHO个体转为代谢不健康,一过性MHO者复合亚临床动脉粥样硬化风险升高(OR 2.52,95%CI 1.89-3.36),从代谢不健康转为健康可降低风险。

要点

  • 基线MHO与亚临床动脉粥样硬化风险无显著关联。
  • 随访4.4年间46.8%的MHO个体转为代谢不健康状态。
  • 一过性MHO者复合亚临床动脉粥样硬化风险升高(OR 2.52,95%CI 1.89-3.36)。

核心结论

  • MHO并非稳定状态,一过性MHO与亚临床动脉粥样硬化(心血管疾病早期阶段)风险升高相关。
  • 作者认为个体可能从早期行为或医学管理中获益,以避免代谢状态恶化和预防动脉粥样硬化及心血管疾病。

研究设计与样本

  • 前瞻性研究,纳入6220名基线无心血管疾病的中国成年人。
  • 肥胖定义为BMI≥25.0 kg/m2;代谢健康定义为NCEP ATP III代谢综合征组分(除腰围外)少于两项。
  • 亚临床动脉粥样硬化分别或联合通过肱踝脉搏波传导速度、脉压和白蛋白尿测量。
  • 采用逆概率加权逻辑回归模型估计亚临床动脉粥样硬化的OR和95%CI。

主要发现

  • 基线MHO占总人群16.3%,占肥胖人群32.8%。
  • 基线MHO与亚临床动脉粥样硬化发病无显著关联。
  • 随访4.4年间,46.8%的MHO个体转为代谢不健康状态。
  • 一过性MHO者复合亚临床动脉粥样硬化风险较代谢健康非肥胖参照组升高(OR 2.52,95%CI 1.89-3.36)。
  • 从代谢不健康转为健康状态可降低结局风险;BMI与亚临床动脉粥样硬化的关联部分由血压和血糖介导。

关键数值与推荐

  • 肥胖标准:BMI≥25.0 kg/m2。
  • 代谢健康标准:NCEP ATP III代谢综合征组分(除腰围外)少于两项。
  • 复合亚临床动脉粥样硬化OR 2.52(95%CI 1.89-3.36),对象为一过性MHO者 vs 代谢健康非肥胖参照组。

临床怎么用

  • 作者认为个体可能从早期行为或医学管理中获益,以避免代谢状态恶化和预防动脉粥样硬化及心血管疾病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The cardiometabolic risk associated with metabolically healthy obesity (MHO) remains the subject of debate. It is unclear whether MHO is a transient condition that affects subclinical atherosclerosis risk. In this study, we aimed to investigate the association of MHO and its transition over time with incident subclinical atherosclerosis. METHODS: A prospective study was conducted with 6220 Chinese adults who were free of cardiovascular disease (CVD) at baseline. Obesity was defined as BMI ≥25.0 kg/m2. Metabolic health was defined as an individual having fewer than two of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP ATP III) criteria for components of the metabolic syndrome (excluding waist circumference). Subclinical atherosclerosis was measured by brachial-ankle pulse wave velocity, pulse pressure and albuminuria, separately or combined. Participants were cross-classified by BMI categories and by metabolic health status and its transition during follow-up. Inverse probability weighted logistic regression models were used to estimate ORs and 95% CIs for subclinical atherosclerosis. RESULTS: The MHO phenotype accounted for 16.3% of the total population and 32.8% of the population with obesity at baseline. Baseline MHO was not significantly associated with incident subclinical atherosclerosis. During a follow-up period of 4.4 years, 46.8% of individuals with MHO developed a metabolically unhealthy status. Those with transient MHO had an increased risk of composite subclinical atherosclerosis compared with those in the metabolically healthy non-obesity reference group (OR 2.52 [95% CI 1.89, 3.36]). A transition from metabolically unhealthy to healthy status was shown to decrease the outcome risk. The relationship between BMI and subclinical atherosclerosis was partly mediated by BP and plasma glucose. CONCLUSIONS/INTERPRETATION: MHO is not a stable condition and transient MHO conferred an increased risk of subclinical atherosclerosis, the early stage of CVD. Hence, individuals may benefit from early behavioural or medical management in order to avoid a deterioration of metabolic status and prevent atherosclerosis and CVD.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Lin L, Zhang J, Jiang L, et al. Transition of metabolic phenotypes and risk of subclinical atherosclerosis according to BMI: a prospective study. Diabetologia. 2020. PMID: 32130460. doi:10.1007/s00125-020-05116-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。